Form 4 for MD Pediatrix Medical Group, Inc.
Accepted 2021-08-31 00:00:00 ET · period of report 2021-08-30 · accession 0001209191-21-054168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-31 | 2021-08-30 | MD | ORDAN MARK S | CEO, Dir | M - OptEx | $17.65 | +95.0K | 303.4K | +46% | +$1.68M |
| D | 2021-08-31 | 2021-08-30 | MD | ORDAN MARK S | CEO, Dir | S - Sale+OE | $35.09 | -95.0K | 208.4K | -31% | -$3.33M |
| D | 2021-08-31 | 2021-08-30 | MD | ORDAN MARK S | CEO, Dir | M - OptEx | $17.65 | -95.0K | 455.3K | -17% | -$1.68M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-30 | M | A | 95,000 | $17.65 | 303,425 | D | — | — | (F1) Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"). |
| 2 | Common | Common Stock | 2021-08-30 | S | D | 95,000 | $35.09 | 208,425 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2021-08-30 | M | D | 95,000 | $17.65 | 455,331 | D | $17.65 · — to 2023-10-10 | 95,000 Common Stock | (F3) Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date. |